Edgewise Therapeutics (EWTX) said Monday that a phase 2 trial of sevasemten to treat patients with Becker muscular dystrophy met its primary endpoint of change from baseline in creatine kinase.
The biopharmaceutical company also said the key secondary endpoint of function demonstrated an improving trend over time in the sevasemten-treated group. It added the drug was well-tolerated, with no new safety concerns in adult or adolescent patients.
Shares of Edgewise Therapeutics were up 22% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.